BIOREGENX, INC. — Earnings
Most recent reported period: FY2025 (Q4) (filed for period ending 2025-12-31) · sourced from SEC EDGAR
Recent earnings · last 8 quarters
| Quarter end | Revenue | YoY | Net Income | YoY | Op. Margin |
|---|---|---|---|---|---|
| 2025-12-31 | $386K | ↓-16.3% | — | — | — |
| 2025-09-30 | $508K | ↓-14.8% | $-81K | ↑+79.6% | -1.7% |
| 2025-06-30 | $446K | ↓-39.2% | $-178K | ↑+83.9% | -24.1% |
| 2025-03-31 | $515K | ↓-6.3% | $-267K | ↑+91.5% | -37.4% |
| 2024-12-31 | $460K | ↓-32.1% | — | — | — |
| 2024-09-30 | $596K | ↓-25.0% | $-395K | ↑+84.3% | -54.9% |
| 2024-06-30 | $734K | ↓-15.0% | $-1M | ↓-86.1% | -141.7% |
| 2024-03-31 | $550K | ↓-48.9% | $-3M | ↓-1271.6% | -560.4% |
Analyst consensus estimates (EPS / Revenue) and implied move from options will land in a follow-up wave. For now, YoY-vs-prior-year-quarter is the surprise proxy.
Last earnings · FY2025 (Q4)
Earnings surprise · last 8 quarters
YoY % change · proxy for analyst surprise until estimates landEPS history · last 10 fiscal years
diluted, GAAP, annualNote: EPS reflects WEIGHTED-AVERAGE diluted shares for each fiscal year. Pre-stock- split values can blow up the early bars if SEC's XBRL data isn't split-adjusted — flagged as a known limitation; cumulative split-adjustment is a follow-up.
Margin trends · 16 quarters
margin trajectory tells the operating-leverage storyGo deeper
BRGX Sankey — flow of dollars
See how revenue waterfalls through every line item to net income for the latest reported quarter, with prior-period comparison.
Open SankeyBRGX Key Metrics — EPS, ROE, ROIC
10 CFA-grade fundamental ratios — EPS, BVPS, ROE, ROA, ROIC, Debt/Equity, Current Ratio. Compare across years.
Open Key Metrics